Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)
Namandjé N. Bumpus(Johns Hopkins University), Craig W. Hendrix(Unknown), Rahul P. Bakshi(Johns Hopkins University), Eugenie Shieh(Johns Hopkins University), Kenneth H. Mayer(Miriam Hospital), Angela D. M. Kashuba(University of North Carolina at Chapel Hill), Heather A. Prince(University of North Carolina at Chapel Hill), Paul G. Richardson(Harvard University), Edward J. Fuchs(Johns Hopkins University), Adriana Andrade(Johns Hopkins University), Peter L. Anderson(University of Colorado Denver), Christine Radebaugh(Johns Hopkins University), Laura McKinstry(Seattle University), Deborah Donnell(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Ayana Moore(Family Health International 360), Mark A. Marzinke(Family Health International 360), Lane R. Bushman(University of Colorado Anschutz Medical Campus), Xin Li(Tianjin Medical University General Hospital), Ruili Wang(University of North Carolina at Chapel Hill), Ilene Wiggins(Johns Hopkins University), Kristine B. Patterson(University of North Carolina at Chapel Hill), Vanessa Elharrar(National Institutes of Health)
Cited by 0
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
|New England Journal of Medicine|2012|3.3k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
|New England Journal of Medicine|2016|1.7k